logo
welcome
TipRanks

TipRanks

Neumora shares look oversold after 80% drop, says Mizuho

TipRanks
Summary
Nutrition label

75% Informative

Neumora Therapeutics stock dropped 80% after negative first Phase 3 KOASTAL-1/K-1 study data for navacaprant in major depressive disorder.

Mizuho keeps an Outperform rating on the company.

The firm says the shares look oversold and has a cash runway to mid-2026 and other pipeline programs.